Quest Diagnostics IncorporatedNYSE: DGX
Health Care · Health Care Services
$202.65
+4.55%
Vol: 40K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Quest Diagnostics back in focus on raised 2026 guidance and lab demand momentumPositive▶
Quest Diagnostics is in focus after a refreshed fair value estimate of $223.25 (up from $218.19) and multiple price target raises from Truist, UBS, Baird, Barclays, and BofA pointing to a constructive risk-reward stance. Quest issued updated 2026 guidance projecting full-year net revenues of $11.78B-$11.90B and reported diluted EPS of $9.58-$9.78. Q1 2026 revenue grew 9.2% y/y with adjusted EPS up 13.1%, driven by consumer testing (QuestHealth.com +35%) and advanced diagnostics. Board authorized 7.5% dividend increase to $0.86 quarterly (15th consecutive annual increase) plus $1B buyback expansion. Stock traded $186.45-$189.88 on May 18. Risk: Canada Post pension sold 5,785 shares; reimbursement pressure remains industry overhang.
May 20Quest Diagnostics declares $0.86 quarterly dividend and prices $500M senior notes offering as analysts raise price targetsPositive▶
Quest Diagnostics declared a quarterly cash dividend of $0.86 per share on May 19, 2026, payable July 22 to shareholders of record July 8. The company priced a $500M senior notes offering due 2036 at 5.000%, with proceeds expected to refinance $500M of 3.45% notes maturing June 1. Q1 2026 results showed 9.2% YoY revenue growth and 13% adjusted EPS gain driven by organic demand, advanced diagnostics, and AI/automation productivity. Truist, UBS, Baird, Barclays and BofA recently raised price targets. Timothy Wentworth, former Walgreens Boots Alliance CEO, was elected to the board. Stock trades near $186.61 with a 12-month consensus price target of $216.42.
May 19No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 18Quest Diagnostics priced $500M of 5.000% senior unsecured notes due 2036 on May 6 to refinance maturing 3.45% senior notes due June 1, 2026.Positive▶
On May 6, 2026, Quest Diagnostics priced $500 million of 5.000% senior unsecured notes due June 30, 2036, with interest payable semiannually beginning December 30, 2026. The proceeds may be used to repay the company's $500M of 3.45% senior notes maturing June 1, 2026. The offering strengthens the balance sheet as Q1 2026 results showed 9.2% YoY revenue growth, prompting raised full-year guidance. The 12-month average analyst price target stands at $216.42 with a Buy consensus from 12 analysts. DGX traded between $186.45-$189.88 on May 18.
May 15Quest Diagnostics shares rose with DGX up $13.19 to $209.50 on May 14 amid continued strength following Q1 beat and a $500M senior notes offering on May 6.Positive▶
On May 14, 2026, Quest Diagnostics (DGX) traded up $13.19 to $209.50 among notable gainers in liquid options, extending positive momentum after recent capital-market and earnings news. On May 6, the company priced a $500 million 5.000% senior unsecured notes offering due June 30, 2036 to strengthen the balance sheet and fund ongoing operations and clinical laboratory network investments. Q1 2026 results (reported April 21) showed revenue up 9.2% YoY to $2.90B with 9.0% organic growth, and adjusted EPS up ~13%, prompting management to raise full-year revenue and EPS guidance. The 12-analyst consensus PT is $216.42 with a Buy rating. Risk: lab-reimbursement and tariff/cost pressures, plus integration of recent tuck-in acquisitions, remain watch items.
May 14Quest Diagnostics priced $500M of 5.0% senior notes due 2036 on May 6 to refinance June maturitiesPositive▶
On May 6, 2026, Quest Diagnostics issued $500M of 5.000% senior unsecured notes due June 30, 2036, with proceeds earmarked for general corporate purposes including repaying $500M of 3.45% notes maturing June 1, 2026. Q1 2026 revenue grew 9.2% YoY to $2.90B (9.0% organic) with diluted EPS of $2.24 (+15.5%); Quest raised full-year revenue and EPS guidance. The company elected former Walgreens/Evernorth/Express Scripts CEO Timothy Wentworth to its board. Stock trades around $190 with P/E of 21x and 1.7% dividend yield, ~10.9% below 52-week high. Risk: rate environment increases interest cost on refinanced debt by ~155 bps.
May 13Quest Diagnostics priced $500M of 5.000% senior notes due 2036 closing May 6 for general corporate purposes including debt repayment, after Q1 beat with EPS $2.50.Positive▶
Quest Diagnostics priced a public offering of $500M aggregate principal amount of 5.000% senior notes due 2036 with proceeds at closing on May 6, 2026 for general corporate purposes including debt repayment. Q1 2026 delivered EPS of $2.50 beating estimates by 5.49%, with revenue of $2.9B (+9.2% YoY) surpassing the $2.83B forecast. Management lifted full-year guidance to adjusted EPS of $10.63-$10.83 and revenue of $11.78-$11.90B. Patients have engaged Quest's AI companion approximately 350,000 times. DGX trades at $190.18 on May 12.
May 12Quest Diagnostics raised FY26 guidance to $11.78-$11.90B revenue and $10.63-$10.83 adj EPS after Q1 revenue of $2.90B (+9.2%) and adj EPS of $2.50 (+13.1%) beat, and priced $500M senior notes due 2036.Positive▶
Quest Diagnostics reported Q1 2026 revenue of $2.90B, up 9.2% YoY with 9.0% organic growth, and adjusted diluted EPS of $2.50 (+13.1%). The company raised full-year 2026 guidance to revenue of $11.78-$11.90B and adjusted EPS of $10.63-$10.83. Stock rose 3.92% to $204 in pre-market following the beat. Quest priced a $500M offering of 5.000% senior notes due 2036 with closing on May 6 for general corporate purposes. Growth drivers include Advanced Diagnostics (double-digit growth), Quest AD-Detect Alzheimer's blood tests, and Co-Lab joint venture with Corewell Health. Risk: wage inflation and fuel costs pressure margins. As of May 7, stock at $190.84.
May 11Quest Diagnostics priced $500M of 5.000% senior notes due 2036 on May 6 after Q1 2026 EPS beat and raised guidance.Positive▶
Quest Diagnostics priced $500 million of 5.000% senior unsecured notes due June 30, 2036, with proceeds expected to refinance the $500 million 3.45% notes maturing June 1, 2026. The debt deal follows a strong Q1 2026 print where revenue rose 9.2% YoY to $2.9B and EPS of $2.50 beat estimates by 5.49%. Full-year 2026 guidance was raised to EPS of $10.82 on revenue of $11.76B. Volume requisitions grew 10.9% on strategic partnership wins. Shares rose 3.92% to $204 in pre-market after the earnings beat.
May 8Quest Diagnostics raised full-year 2026 guidance after beating Q1 earnings with 9.2% YoY revenue growth to $2.9B and $2.50 EPS.Positive▶
Quest Diagnostics reported Q1 2026 results on April 29-30, 2026 with EPS of $2.50 (beat 5.49%) and revenue of $2.9B (up 9.2% YoY), surpassing consensus estimates of $2.83B. The company raised full-year 2026 guidance to $10.82 EPS with revenue of $11.76B. In early May, the company priced $500 million of 5.00% senior notes due 2036. The stock jumped 3.92% to $204 in pre-market trading. Analyst Baird raised price target to $229 from $224 on April 22, 2026.
May 7Quest Diagnostics reports Q1 2026 revenues up 9.2% to $2.90B and raises full-year EPS guidance to $10.63-$10.83 on May 5, 2026.Positive▶
Quest Diagnostics delivered strong first quarter results with 9.0% organic revenue growth and announced it will use $500 million in newly priced senior notes (due 2036) to repay maturing debt. The company raised full-year 2026 guidance for both revenue ($11.78-$11.90B) and EPS, signaling confidence in continued diagnostic demand momentum and pricing power. Results reflect solid execution across core testing services and oncology diagnostics.
May 6Quest Diagnostics raises 2026 guidance after Q1 beat; launches AI companion for test analysisPositive▶
Quest Diagnostics reported Q1 2026 net revenues of $2.90 billion, up 9.2%, with diluted EPS up 15.5% to $2.24. Full-year guidance raised to $11.78-$11.90 billion revenue and $10.63-$10.83 adjusted EPS. AI Companion launch powered by Google Gemini helps patients understand lab results. Advanced Diagnostics and AD-Detect blood tests drove double-digit growth. Price target raised to $229 from $224 at Baird.
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.